背景(考古学)
支柱
氧化应激
心力衰竭
第一行
炎症
机制(生物学)
生物信息学
医学
药理学
计算生物学
生物
内科学
工程类
物理
古生物学
结构工程
量子力学
作者
Theresa Brand,Ann-Kathrin Lukannek,Valérie Jahns,Roland Jahns,Kristina Lorenz
标识
DOI:10.1016/j.coph.2024.102458
摘要
β-blockers are a solid pillar in the treatment of cardiovascular diseases. However, they are highly discussed regarding effectiveness for certain indications and side-effects. Even though there are up to 20 licensed compounds, only four are used for heart failure (HF) therapy. On the receptor level several key characteristics seem to influence the clinical outcome: subtype selectivity, antagonistic vs (inverse/biased) agonistic properties and -in particular- ancillary capacities. On a molecular level, divergent and novel signaling patterns are being identified and extra-cardiac effects on e.g. inflammation, metabolism and oxidative stress are highlighted. This review discusses different well-known and newly discovered characteristics that need to be considered for HF therapy and in the context of co-morbidities.
科研通智能强力驱动
Strongly Powered by AbleSci AI